Safety And Efficacy From The Surpass Trial With Adp-A2m4cd8, A Spear T-Cell Therapy Incorporating A Cd8 Alpha Co-Receptor And An Affinity Optimized Tcr Targeting Mage-A4

D. S. Hong, J. M. Clarke,A. Asch, J. Charlson, T. M. Johanns,E. Calvo,V. Boni,M. J. De Miguel,V. Moreno Garcia,D. P. Lawrence,M. O. Butler, J. Zugazagoitia,M. A. Blum Murphy,P. Kebriaei,G. R. Blumenschein,Q. Lin, H. Danesi, E. Norry

ANNALS OF ONCOLOGY（2021）

引用 4|浏览6

暂无评分

摘要

The ongoing phase 1 SURPASS trial (NCT04044859) evaluates safety and efficacy of next-generation ADP-A2M4CD8 SPEAR T-cells co-expressing the CD8α co-receptor with the engineered T-cell receptor (TCR) targeting MAGE-A4.

查看译文

关键词

tcr,t-cell,co-receptor

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要